Erectile dysfunction – a diabetologist point of view Review article
Article Sidebar
Published:
Mar 31, 2021
Keywords:
phosphodiesterase 5 inhibitors, erectile dysfunction
Main Article Content
Abstract
The prevalence of erectile dysfunction among diabetic patients is not exactly known. There is no doubt, however, that due to the complex nature of complications of poorly controlled diabetes, related to both blood vessel and nervous system damage, the frequency of these disorders increases with the duration of the disease. The coexistence of hypertension and obesity is also important, especially in the case of patients with type 2 diabetes. Our sexuality is slowly ceasing to be a taboo subject, so we are talking more and more often about the treatment of erectile dysfunction. In this article we present this problem from the diabetic point of view.
Article Details
How to Cite
Duda-Król , W. B., Wełnicki , M., & Mamcarz , A. (2021). Erectile dysfunction – a diabetologist point of view. Medycyna Faktow (J EBM), 14(1(50), 28-31. https://doi.org/10.24292/01.MF.0121.2
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-6.
2. Rosen RC, Cappelleri JC, Smith MD et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999; 11: 319-26.
3. Modrzewski A, Jakima S, Zieliński H et al. Ocena zachowań seksualnych personelu lotniczego. Seksuologia Polska. 2003; 1: 3-7.
4. McCulloch DK, Campbell IW, Wu FC et al. The prevalence of diabetic impotence. Diabetologia. 1980; 18: 279-83.
5. De Berardis G, Franciosi M, Belfiglio M et al. Erectile dysfunction and quality of life in type 2 diabetic patients. A serious problem too often overlooked. Diabetes Care. 2002; 25: 284-91.
6. Giuliano FA, Leriche A, Jaudinot EO et al. Prevalence of erectile dysfunction among 7,689 patients with diabetes or hypertension, or both. Urology. 2004; 64: 1196-201.
7. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009; 6: 1232-47.
8. Dadej R. Zaburzenia erekcji – fizjologia, epidemiologia, patofizjologia, diagnostyka i leczenie. Przew Lek. 2001; 4: 106-11.
9. Hatzimouratidis K, Eardley I, Giuliano F et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. European Association of Urology 2015 (access: 2.01.2021).
10. Green JSA, Holden STR, Ingram P et al. An investigation of erectile dysfunction in Gwent, Wales. BJU Int. 2001; 88: 551-3.
11. Yuan P, Ma D, Gao X et al. Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus. Front Pharmacol. 2020; 11: 1257. http://doi.org/10.3389/fphar.2020.01257.
12. Altabas V, Altabas K. DPP-4 inhibition improves a sexual condition? Med Hypotheses. 2015; 85(2): 124-6. http://doi.org/10.1016/j.mehy.2015.04.011.
13. Trocóniz IF, Tillmann C, Staab A J et al. Tadalafil population pharmacokinetics in patients with erectile dysfunction. Eur J Clin Pharmacol. 2007; 63(6): 583‐90. http://doi.org/10.1007/s00228-007-0297-1.
14. Lewis RW, Sadovsky R, Eardley I et al. The efficacy of tadalafil in clinical populations. J Sex Med. 2005; 2(4): 517‐31. http://doi.org/10.1111/j.1743-6109.2005.00068.x.
15. Forgue ST, Phillips DL, Bedding AW et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007; 63(1): 24‐35. http://doi.org/10.1111/j.1365-2125.2006.02726.x.
16. Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010; 4: 159‐71. http://doi.org/10.2147/dddt.s9067.
2. Rosen RC, Cappelleri JC, Smith MD et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999; 11: 319-26.
3. Modrzewski A, Jakima S, Zieliński H et al. Ocena zachowań seksualnych personelu lotniczego. Seksuologia Polska. 2003; 1: 3-7.
4. McCulloch DK, Campbell IW, Wu FC et al. The prevalence of diabetic impotence. Diabetologia. 1980; 18: 279-83.
5. De Berardis G, Franciosi M, Belfiglio M et al. Erectile dysfunction and quality of life in type 2 diabetic patients. A serious problem too often overlooked. Diabetes Care. 2002; 25: 284-91.
6. Giuliano FA, Leriche A, Jaudinot EO et al. Prevalence of erectile dysfunction among 7,689 patients with diabetes or hypertension, or both. Urology. 2004; 64: 1196-201.
7. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009; 6: 1232-47.
8. Dadej R. Zaburzenia erekcji – fizjologia, epidemiologia, patofizjologia, diagnostyka i leczenie. Przew Lek. 2001; 4: 106-11.
9. Hatzimouratidis K, Eardley I, Giuliano F et al. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. European Association of Urology 2015 (access: 2.01.2021).
10. Green JSA, Holden STR, Ingram P et al. An investigation of erectile dysfunction in Gwent, Wales. BJU Int. 2001; 88: 551-3.
11. Yuan P, Ma D, Gao X et al. Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus. Front Pharmacol. 2020; 11: 1257. http://doi.org/10.3389/fphar.2020.01257.
12. Altabas V, Altabas K. DPP-4 inhibition improves a sexual condition? Med Hypotheses. 2015; 85(2): 124-6. http://doi.org/10.1016/j.mehy.2015.04.011.
13. Trocóniz IF, Tillmann C, Staab A J et al. Tadalafil population pharmacokinetics in patients with erectile dysfunction. Eur J Clin Pharmacol. 2007; 63(6): 583‐90. http://doi.org/10.1007/s00228-007-0297-1.
14. Lewis RW, Sadovsky R, Eardley I et al. The efficacy of tadalafil in clinical populations. J Sex Med. 2005; 2(4): 517‐31. http://doi.org/10.1111/j.1743-6109.2005.00068.x.
15. Forgue ST, Phillips DL, Bedding AW et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007; 63(1): 24‐35. http://doi.org/10.1111/j.1365-2125.2006.02726.x.
16. Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010; 4: 159‐71. http://doi.org/10.2147/dddt.s9067.